Palivizumab Use In Japanese Infants And Children With Immunocompromised Conditions

A total of 27/28 (96%) immunocompromised Japanese children received ≥4 doses of palivizumab. No respiratory syncytial virus-associated hospitalizations occurred. Mean palivizumab trough concentrations were 59.0 and 91.8 μg/mL 30 days after the 1st and 4th doses, respectively. Of 28 subjects, 27 (96%